Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

TET1 mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

TET1 mutation	Non Small Cell Lung Cancer	TET1 mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
TET1 mutation	Melanoma	TET1 mutation	Melanoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
TET1 mutation	Squamous Cell Carcinoma of Head and Neck	TET1 mutation	Squamous Cell Carcinoma of Head and Neck	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
TET1 mutation	Gastroesophageal Cancer	TET1 mutation	Gastroesophageal Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
TET1 mutation	Bladder Cancer	TET1 mutation	Bladder Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
TET1 mutation	Colorectal Cancer	TET1 mutation	Colorectal Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
TET1 mutation	Colon Cancer	TET1 mutation	Colon Cancer	lapatinib Sensitive: C3 – Early Trials lapatinib Sensitive : C3	lapatinib Sensitive: C3 – Early Trials lapatinib Sensitive : C3
TET1 mutation	Colon Cancer	TET1 mutation	Colon Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3